FLT3, or Fms-like tyrosine kinase 3, is a protein implicated in certain types of leukemia. FLT3 inhibitors are a class of pharmaceuticals designed to thwart the overactive FLT3 signaling common in these leukemias. By blocking FLT3, these inhibitors aim to impede cancer cell growth and division, offering new hope to patients. Targeted therapies like FLT3 inhibitors demonstrate the remarkable progress made in the field of oncology and contribute to more effective, less toxic treatments for leukemia and other cancers.